Last reviewed · How we verify
Anti-VEGF treatment
Anti-VEGF treatment works by inhibiting the vascular endothelial growth factor (VEGF) pathway, which is involved in angiogenesis and tumor growth.
Anti-VEGF treatment works by inhibiting the vascular endothelial growth factor (VEGF) pathway, which is involved in angiogenesis and tumor growth. Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic renal cell carcinoma.
At a glance
| Generic name | Anti-VEGF treatment |
|---|---|
| Sponsor | Vastra Gotaland Region |
| Drug class | Anti-angiogenic agent |
| Target | VEGF |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By blocking VEGF, Anti-VEGF treatment reduces the formation of new blood vessels that supply nutrients and oxygen to tumors, thereby inhibiting tumor growth and metastasis. This mechanism is particularly effective in treating cancers that are dependent on angiogenesis for growth and survival.
Approved indications
- Metastatic colorectal cancer
- Metastatic non-small cell lung cancer
- Metastatic renal cell carcinoma
Common side effects
- Increased risk of hypertension
- Increased risk of proteinuria
- Fatigue
- Headache
- Nausea
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (PHASE3)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-VEGF treatment CI brief — competitive landscape report
- Anti-VEGF treatment updates RSS · CI watch RSS
- Vastra Gotaland Region portfolio CI